Yufeng Zhang1, Dai Jing2, Daniel Buser3, Anton Sculean4, Fatiha Chandad5, Richard J Miron6,7,8,9. 1. The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China. zyf@whu.edu.cn. 2. The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China. 3. Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, Bern, Switzerland. 4. Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland. 5. University of Laval, Dental School, Quebec City, Canada. 6. The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China. richard.miron@zmk.unibe.ch. 7. Department of Oral Surgery and Stomatology, School of Dental Medicine, University of Bern, Bern, Switzerland. richard.miron@zmk.unibe.ch. 8. Department of Periodontology, School of Dental Medicine, University of Bern, Bern, Switzerland. richard.miron@zmk.unibe.ch. 9. University of Laval, Dental School, Quebec City, Canada. richard.miron@zmk.unibe.ch.
Abstract
OBJECTIVES: Enamel matrix derivative (EMD) has been successfully used for the regeneration of periodontal tissues including new cementum, periodontal ligament, and alveolar bone. Combination of EMD with bone grafting materials has however generated variable clinical results. Recently, we have demonstrated that a new formulation of EMD in a liquid carrier system (Osteogain®) has improved physicochemical properties for the adsorption of EMD to a bone grafting material. The aim of the present study was to investigate the regenerative potential of Osteogain®, in combination with a bone graft, on new bone formation in a rat femur defect model. MATERIALS AND METHODS: Fifty-four critically sized femur defects (3 mm in diameter) were created bilaterally in 27 rats and treated following the group allocation: (1) drilled unfilled control, (2) a natural bone mineral (NBM), and (3) NBM + Osteogain®. All defects were histologically analyzed at 2, 4, and 8 weeks after surgical intervention. Micro-CT analysis, hematoxylin and eosin (H&E) staining, and Safranin O staining were performed to quantify new bone formation. RESULTS: Significantly more new bone formation was observed in defects treated with NBM + Osteogain® at both 4 and 8 weeks when compared to NBM alone and the control unfilled defects (P < 0.05). Histologically, the formation of more mature mineralized bone with the presence of osteocytes were found more commonly in defects treated with Osteogain® + NBM at 8 weeks post-healing when compared to NBM alone. CONCLUSIONS: The present study demonstrate that Osteogain® in combination with a bone grafting material improves the speed and quality of new bone formation in rat osseous defects. CLINICAL RELEVANCE: Future clinical research are now warranted to fully characterize the benefits of Osteogain®, a new formulation of enamel matrix proteins delivered in liquid formation when used in combination with a bone grafting material.
OBJECTIVES: Enamel matrix derivative (EMD) has been successfully used for the regeneration of periodontal tissues including new cementum, periodontal ligament, and alveolar bone. Combination of EMD with bone grafting materials has however generated variable clinical results. Recently, we have demonstrated that a new formulation of EMD in a liquid carrier system (Osteogain®) has improved physicochemical properties for the adsorption of EMD to a bone grafting material. The aim of the present study was to investigate the regenerative potential of Osteogain®, in combination with a bone graft, on new bone formation in a rat femur defect model. MATERIALS AND METHODS: Fifty-four critically sized femur defects (3 mm in diameter) were created bilaterally in 27 rats and treated following the group allocation: (1) drilled unfilled control, (2) a natural bone mineral (NBM), and (3) NBM + Osteogain®. All defects were histologically analyzed at 2, 4, and 8 weeks after surgical intervention. Micro-CT analysis, hematoxylin and eosin (H&E) staining, and Safranin O staining were performed to quantify new bone formation. RESULTS: Significantly more new bone formation was observed in defects treated with NBM + Osteogain® at both 4 and 8 weeks when compared to NBM alone and the control unfilled defects (P < 0.05). Histologically, the formation of more mature mineralized bone with the presence of osteocytes were found more commonly in defects treated with Osteogain® + NBM at 8 weeks post-healing when compared to NBM alone. CONCLUSIONS: The present study demonstrate that Osteogain® in combination with a bone grafting material improves the speed and quality of new bone formation in ratosseous defects. CLINICAL RELEVANCE: Future clinical research are now warranted to fully characterize the benefits of Osteogain®, a new formulation of enamel matrix proteins delivered in liquid formation when used in combination with a bone grafting material.
Entities:
Keywords:
BioOss; Bone grafting materials; Emdogain; Enamel matrix derivative (EMD); Natural bone mineral
Authors: John D Bartlett; Bernhard Ganss; Michel Goldberg; Janet Moradian-Oldak; Michael L Paine; Malcolm L Snead; Xin Wen; Shane N White; Yan L Zhou Journal: Curr Top Dev Biol Date: 2006 Impact factor: 4.897
Authors: Bradshaw M Stout; Brian J Alent; Peter Pedalino; Ryan Holbrook; Jelica Gluhak-Heinrich; Yong Cui; Marie A Harris; Anja C Gemperli; David L Cochran; David E Deas; Stephen E Harris Journal: J Periodontol Date: 2013-08-06 Impact factor: 6.993
Authors: Daniël A W Oortgiesen; Gert J Meijer; Antonius L J J Bronckers; X Frank Walboomers; John A Jansen Journal: Clin Oral Investig Date: 2012-05-03 Impact factor: 3.573
Authors: Richard J Miron; Oana M Caluseru; Vincent Guillemette; Yufeng Zhang; Anja C Gemperli; Fatiha Chandad; Anton Sculean Journal: PLoS One Date: 2013-08-12 Impact factor: 3.240
Authors: Jung Soo Park; Andreas Max Pabst; Maximilian Ackermann; Maximilian Moergel; Junho Jung; Adrian Kasaj Journal: Clin Oral Investig Date: 2017-07-11 Impact factor: 3.573